TianjinCIH
Welcome,         Profile    Billing    Logout  
 75 Trials 
61 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tang, Yong
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
Ba, Yi
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting
3
351
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan
RemeGen Co., Ltd.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
12/24
06/25
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Recruiting
3
642
RoW
HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos
Shanghai Henlius Biotech
Gastric Cancer
10/23
10/24
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Not yet recruiting
2
81
NA
KH903 + Paclitaxel, Placebo + Paclitaxel
Chengdu Kanghong Biotech Co., Ltd.
Gastric Cancer, Gastroesophageal Cancer
01/22
01/22
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting
2
103
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
01/25
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting
2
20
RoW
irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin
Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd.
Biliary Tract Carcinoma
12/24
12/25
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody), Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Not yet recruiting
1
60
NA
SCT-I10A, SCT200, Chemotherapy
Sinocelltech Ltd.
Esophageal Squamous Cell Carcinoma, Colorectal Cancer
08/22
12/22
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
63
RoW
RC98, RC98 for Injection
RemeGen Co., Ltd.
Solid Tumors
12/23
12/23
TQB3454-I-02, NCT04481607: A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Recruiting
1
96
RoW
TQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor or Hematologic Tumor
12/22
12/22
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Recruiting
1
24
RoW
RC48-ADC, RC48-ADC injection, RC98, RC98 injection
RemeGen Co., Ltd.
Gastric Cancer
05/24
09/24
NCT05804864: A Study of KM501 in Patients With Solid Tumors

Not yet recruiting
1
96
RoW
KM501
Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumors
12/26
12/27
Huang, dingzhi
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
TQB2450-III-12, NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Not yet recruiting
3
570
RoW
TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Squamous Non-Small Cell Lung Carcinoma
10/24
10/25
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting
3
518
RoW
TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
08/25
12/25
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
2/3
1080
NA
HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib
Hansoh BioMedical R&D Company
Non-Squamous Non-Small Cell Lung Cancer
06/26
06/30
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Recruiting
2
13
RoW
Almonertinib, Investigational Product
Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Adenosquamous Carcinoma
12/23
06/25
NCT06143735: A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Not yet recruiting
2
99
RoW
Efgbemalenograstim alfa
Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
12/24
06/26
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
NCT05435274: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Recruiting
1/2
380
RoW
HS-10376
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Non-Small-Cell Lung Cancer
10/24
10/25
NCT05991349: A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
180
RoW
IBI129
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
11/24
05/25
NCT05315180: A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Recruiting
1
80
RoW
BPI-421286
Betta Pharmaceuticals Co., Ltd.
Malignant Neoplasms, Metastatic Cancer
07/23
07/23
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
NCT05940116: A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Not yet recruiting
1
322
RoW
HS-20117, PM1080
Hansoh BioMedical R&D Company
Non-Small Cell Lung Cancer, Solid Tumor
07/25
07/27
Yang, Yang
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Recruiting
3
426
RoW
Camrelizumab, radiotherapy
Zhigang Li, Jiangsu HengRui Medicine Co., Ltd.
Resectable Esophageal Squamous Cell Carcinoma
12/28
12/30
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting
1/2
80
US, RoW
HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule
Shanghai Huaota Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, NSCLC
08/25
08/25
Li, Hongli
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

Recruiting
2
83
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043

Not yet recruiting
2
202
RoW
ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
Abbisko Therapeutics Co, Ltd
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
11/29
06/30
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
TQB2102-Ib/II-01, NCT06431490: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Recruiting
1/2
103
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Biliary Tract Cancer
05/25
12/25
SHR-A1811-208, NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Recruiting
1/2
364
RoW
SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing Advanced Solid Tumors
11/26
12/26
Deng, Ting
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Not yet recruiting
2
138
RoW
AK105, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MSI-H or dMMR Advanced Solid Tumors
12/22
12/22
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting
2
276
RoW
LM302+Toripalimab, LM302+JS001
LaNova Medicines Zhejiang Co., Ltd.
Gastric Cancer, Pancreatic Cancer
07/25
01/26
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting
1/2
260
RoW
Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Advanced Malignant Solid Tumors
05/28
12/28
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1
470
US, RoW
IBI343
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed
Locally Advanced Unresectable or Metastatic Solid Tumors
12/25
12/25
NCT05751356: TR128 in Patients With Advanced Solid Tumors

Recruiting
1
50
RoW
TR128
Tarapeutics Science Inc.
Advanced Solid Tumor
08/25
12/25
Liu, Rui
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
TSL-CM-TSL1502-Ⅱ, NCT05420779: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Recruiting
2
125
RoW
TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Breast Cancer Metastatic
12/24
06/26
NCT05536089: ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation

Recruiting
N/A
2000
RoW
a multi-locus blood-based assay
Singlera Genomics Inc., Second Affiliated Hospital, School of Medicine, Zhejiang University
Cancer Colorectal
09/28
12/28
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Completed
N/A
2430
RoW
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc.
Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma
06/23
07/23
NCT05336058: Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer

Completed
N/A
1140
RoW
No intervention
Singlera Genomics Inc., Fudan University
Stomach Cancer
02/24
02/24
NCT05432128: To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

Recruiting
N/A
600
RoW
Singlera Genomics Inc., China-Japan Friendship Hospital
Lung Cancer
12/25
12/25
NCT05159544: The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population

Recruiting
N/A
60000
RoW
Singlera Genomics Inc., Fudan University
Cancer
07/24
12/24
NCT05444491: Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer

Recruiting
N/A
1200
RoW
Singlera Genomics Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
06/25
06/25
NCT05485077: A Prospective Cohort Study on Colorectal Cancer Screening in Community Population

Recruiting
N/A
18000
RoW
Singlera Genomics Inc., Peking University Shougang Hospital
Colorectal Cancer
07/28
07/28
Ning, Tao
NCT05299697: A Study of TG103 Injection in Overweight or Obesity

Recruiting
2
195
RoW
TG103 15 mg, TG103 22.5 mg, Placebo
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight or Obesity
06/23
09/23
Han, Rubing
No trials found
Jiang, Richeng
No trials found
Zhongjie, Chen
No trials found
Richeng, Richeng
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tang, Yong
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
Ba, Yi
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting
3
351
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan
RemeGen Co., Ltd.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
12/24
06/25
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Recruiting
3
642
RoW
HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos
Shanghai Henlius Biotech
Gastric Cancer
10/23
10/24
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Not yet recruiting
2
81
NA
KH903 + Paclitaxel, Placebo + Paclitaxel
Chengdu Kanghong Biotech Co., Ltd.
Gastric Cancer, Gastroesophageal Cancer
01/22
01/22
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Active, not recruiting
2
103
RoW
Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan
Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany
BRAF V600E, Metastatic Colorectal Cancer
12/23
01/25
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma

Not yet recruiting
2
20
RoW
irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin
Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd.
Biliary Tract Carcinoma
12/24
12/25
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody), Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC

Not yet recruiting
1
60
NA
SCT-I10A, SCT200, Chemotherapy
Sinocelltech Ltd.
Esophageal Squamous Cell Carcinoma, Colorectal Cancer
08/22
12/22
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
63
RoW
RC98, RC98 for Injection
RemeGen Co., Ltd.
Solid Tumors
12/23
12/23
TQB3454-I-02, NCT04481607: A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Recruiting
1
96
RoW
TQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor or Hematologic Tumor
12/22
12/22
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Recruiting
1
24
RoW
RC48-ADC, RC48-ADC injection, RC98, RC98 injection
RemeGen Co., Ltd.
Gastric Cancer
05/24
09/24
NCT05804864: A Study of KM501 in Patients With Solid Tumors

Not yet recruiting
1
96
RoW
KM501
Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Solid Tumors
12/26
12/27
Huang, dingzhi
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
TQB2450-III-12, NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Not yet recruiting
3
570
RoW
TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Squamous Non-Small Cell Lung Carcinoma
10/24
10/25
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting
3
518
RoW
TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
08/25
12/25
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
2/3
1080
NA
HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib
Hansoh BioMedical R&D Company
Non-Squamous Non-Small Cell Lung Cancer
06/26
06/30
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Recruiting
2
13
RoW
Almonertinib, Investigational Product
Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Adenosquamous Carcinoma
12/23
06/25
NCT06143735: A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Not yet recruiting
2
99
RoW
Efgbemalenograstim alfa
Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
12/24
06/26
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
NCT05435274: Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Recruiting
1/2
380
RoW
HS-10376
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Non-Small-Cell Lung Cancer
10/24
10/25
NCT05991349: A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
180
RoW
IBI129
Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor
11/24
05/25
NCT05315180: A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Recruiting
1
80
RoW
BPI-421286
Betta Pharmaceuticals Co., Ltd.
Malignant Neoplasms, Metastatic Cancer
07/23
07/23
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
NCT05940116: A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Not yet recruiting
1
322
RoW
HS-20117, PM1080
Hansoh BioMedical R&D Company
Non-Small Cell Lung Cancer, Solid Tumor
07/25
07/27
Yang, Yang
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

Recruiting
3
426
RoW
Camrelizumab, radiotherapy
Zhigang Li, Jiangsu HengRui Medicine Co., Ltd.
Resectable Esophageal Squamous Cell Carcinoma
12/28
12/30
NCT05417321: A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting
1/2
80
US, RoW
HB0036, Anti-PD-L1 and anti-TIGIT bifunctional molecule
Shanghai Huaota Biopharmaceutical Co., Ltd.
Advanced Solid Tumor, NSCLC
08/25
08/25
Li, Hongli
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

Recruiting
2
83
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043

Not yet recruiting
2
202
RoW
ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX
Abbisko Therapeutics Co, Ltd
HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
11/29
06/30
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
TQB2102-Ib/II-01, NCT06431490: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Recruiting
1/2
103
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Biliary Tract Cancer
05/25
12/25
SHR-A1811-208, NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Recruiting
1/2
364
RoW
SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing Advanced Solid Tumors
11/26
12/26
Deng, Ting
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Not yet recruiting
2
138
RoW
AK105, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MSI-H or dMMR Advanced Solid Tumors
12/22
12/22
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Terminated
2
6
RoW
Infigratinib, BGJ398, BBP-831
LianBio LLC
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/24
05/24
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting
2
276
RoW
LM302+Toripalimab, LM302+JS001
LaNova Medicines Zhejiang Co., Ltd.
Gastric Cancer, Pancreatic Cancer
07/25
01/26
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting
1/2
260
RoW
Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Advanced Malignant Solid Tumors
05/28
12/28
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1
470
US, RoW
IBI343
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed
Locally Advanced Unresectable or Metastatic Solid Tumors
12/25
12/25
NCT05751356: TR128 in Patients With Advanced Solid Tumors

Recruiting
1
50
RoW
TR128
Tarapeutics Science Inc.
Advanced Solid Tumor
08/25
12/25
Liu, Rui
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A

Completed
3
176
RoW
PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution
Tasly GeneNet Pharmaceuticals Co., Ltd
Charcot-Marie-Tooth Type 1A
03/24
03/24
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
TSL-CM-TSL1502-Ⅱ, NCT05420779: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Recruiting
2
125
RoW
TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Breast Cancer Metastatic
12/24
06/26
NCT05536089: ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation

Recruiting
N/A
2000
RoW
a multi-locus blood-based assay
Singlera Genomics Inc., Second Affiliated Hospital, School of Medicine, Zhejiang University
Cancer Colorectal
09/28
12/28
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Completed
N/A
2430
RoW
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc.
Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma
06/23
07/23
NCT05336058: Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer

Completed
N/A
1140
RoW
No intervention
Singlera Genomics Inc., Fudan University
Stomach Cancer
02/24
02/24
NCT05432128: To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

Recruiting
N/A
600
RoW
Singlera Genomics Inc., China-Japan Friendship Hospital
Lung Cancer
12/25
12/25
NCT05159544: The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population

Recruiting
N/A
60000
RoW
Singlera Genomics Inc., Fudan University
Cancer
07/24
12/24
NCT05444491: Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer

Recruiting
N/A
1200
RoW
Singlera Genomics Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
06/25
06/25
NCT05485077: A Prospective Cohort Study on Colorectal Cancer Screening in Community Population

Recruiting
N/A
18000
RoW
Singlera Genomics Inc., Peking University Shougang Hospital
Colorectal Cancer
07/28
07/28
Ning, Tao
NCT05299697: A Study of TG103 Injection in Overweight or Obesity

Recruiting
2
195
RoW
TG103 15 mg, TG103 22.5 mg, Placebo
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Overweight or Obesity
06/23
09/23
Han, Rubing
No trials found
Jiang, Richeng
No trials found
Zhongjie, Chen
No trials found
Richeng, Richeng
No trials found

Download Options